Treatment of hairy cell leukemia with cladribine;Liječenje leukemije vlasastih stanica kladribinom

Lijecnicki Vjesnik

Volumn 129, Issue 3-4, 2007, Pages 80-83

  Aurer, Igor ^a,b   Mitrović, Zdravko ^a   Kovačević Metelko, Jasminka ^a   Radman, Ivo ^a   Bašić Kinda, Sandra ^a   Gjadrov Kuveždić, Koraljka ^b   Jakić Razumović, Jasminka ^a   Dubravčic, Klara ^b   Ries, Sunčica ^b   Nola, Marin ^a   Zupančić Šalek, Silva ^a   Labar, Boris ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Drug therapy; Cladribine; Leukemia, hairy cell; Therapeutic use, administration and dosage, adverse effects; Therapeutic use, administration and dosage, adverse effects; Antineoplastic agents

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE;

ADULT; AGED; ARTICLE; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; MALE; MIDDLE AGED; MORTALITY; REMISSION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE;

EID: 34249777553     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Foucar K, Catovsky D, Hairy cell leukemia. U: Jaffe ES, Hariss NL, Stein H, Vardiman JW, ur. World health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001, str. 138-41.
2. Cheson BD, Sorensen JM, Vena DA i sur. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-15.
3. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-6.
4. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26.
5. Chadha P, Rademaker AW, Mendiratta P i sur. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241-6.
6. Zinzani PL, Tani M, Marchi E i sur. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004;89:309-13.
7. Estey EM, Kurzrock R, Kantarjian HM i sur. Treatment of hairy cell leukemia with 2-chloroxyadenosine (2-CdA). Blood 1992;79:882-7.
8. Robak T, Blasinska-Morawiec M, Krykowski E i sur. 2-chlorodeoxya-denosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1999;22:107-11.
9. Damasio EE, Resegotti L, Masoudi B i sur. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia. Recenti Prog Med 1998;89:68-73.
10. Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999;84:22-5.
11. von Rohr A, Schmitz SF, Tichelli A i sur. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002;13:1641-9.
12. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov. March 31, 2003.
13. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-80.
14. Dawson B, Trapp RG. Basic & clinical biostatistics. 3. izd. New York: McGraw-Hill; 2001, str. 218-21.
15. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-3.
16. Thomas DA, O'Brien S, Bueso-Ramos C i sur. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906-11.
17. Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999;93:2471-7.
18. Kurzrock R, Strom SS, Estey E i sur. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997;15:1803-10.
19. Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998;92:1160-4.